Crescent Biopharma, Inc.
↗Waltham, USA
Crescent Biopharma is a clinical-stage biotechnology company focused on developing next-generation oncology therapeutics. The company's pipeline centers on a PD-1 x VEGF bispecific antibody (CR-001) and a portfolio of antibody-drug conjugates (ADCs) designed to treat various solid tumors.
Formed through a reverse merger with GlycoMimetics, Inc. in 2024, the company is publicly traded on the NASDAQ. Crescent is actively advancing its clinical programs, including the global Phase 1/2 ASCEND trial for its lead candidate, CR-001, and is pursuing strategic collaborations to accelerate its combination therapy strategy.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:$10M-$20M
Founded:2024
Ownership:public
Status:operating
FUNDING
Stage:Public
Total Raised:$185M (Private Placement Dec 2025)
Investors:Leading healthcare investors (participated in $185M private placement)
STOCK
Exchange:NASDAQ
Ticker:CBIO
Market Cap:$0.66B
PIPELINE
Stage:Phase 1/2
Lead Drug Stage:Phase 1/2
Modalities:Bispecific antibody, Antibody-drug conjugate (ADC)
Active Trials:1
Trial Phases:Phase 1: 1 | Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (Strategic collaboration for CR-001 and CR-003)
COMPETITION
Position:Emerging
Competitors:Jazz Pharmaceuticals, Kite Pharma, Advanced Accelerator Applications, Akeso, Summit Therapeutics
LEADERSHIP
Key Executives:
Joshua Brumm - CEO
Ellie Im - Chief Medical Officer
LINKS
Website:crescentbiopharma.com
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Crescent Biopharma, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Crescent Biopharma, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.